Global Duchenne Muscular Dystrophy Market

Global Duchenne Muscular Dystrophy Market Size, Share, Growth Analysis, By Therapy(Mutation Suppression, Exon Skipping Approach), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2024-2031

Report ID: SQSG35I2036 | Region: Global | Published Date: April, 2024
Pages: 157 | Tables: 63 | Figures: 75

Global Duchenne Muscular Dystrophy Market Competitive Landscape

Global duchenne muscular dystrophy market is competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D.

Top Players in the Global Duchenne Muscular Dystrophy Market

  • Pfizer Inc.
  • PTC Therapeutics Inc.
  • Sarepta Therapeutics
  • Santhera Pharmaceuticals
  • Solid Biosciences
  • Catabasis Pharmaceuticals
  • Summit Therapeutics
  • NS Pharma, Inc.
  • Wave Life Sciences
  • BioMarin Pharmaceutical Inc.
  • ReveraGen BioPharma Inc.
  • Bristol-Myers Squibb
  • Roche Holding AG
  • Daiichi Sankyo Company, Limited
  • Vertex Pharmaceuticals
  • Italfarmaco S.p.A.
  • Biogen
  • Ultragenyx Pharmaceutical Inc.
  • FibroGen
  • Marathon Pharmaceuticals, LLC

Duchenne Muscular Dystrophy Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Duchenne Muscular Dystrophy Market size was valued at USD 1301.44 million in 2019 and is poised to grow from USD 1362.61 million in 2023 to USD 2060.11 million by 2031, growing at a CAGR of 4.7% in the forecast period (2024-2031).

Global duchenne muscular dystrophy market is competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Pfizer Inc.', 'PTC Therapeutics Inc.', 'Sarepta Therapeutics', 'Santhera Pharmaceuticals', 'Solid Biosciences', 'Catabasis Pharmaceuticals', 'Summit Therapeutics', 'NS Pharma, Inc.', 'Wave Life Sciences', 'BioMarin Pharmaceutical Inc.', 'ReveraGen BioPharma Inc.', 'Bristol-Myers Squibb', 'Roche Holding AG', 'Daiichi Sankyo Company, Limited', 'Vertex Pharmaceuticals', 'Italfarmaco S.p.A.', 'Biogen', 'Ultragenyx Pharmaceutical Inc.', 'FibroGen', 'Marathon Pharmaceuticals, LLC'

Prevalence of duchenne muscular dystrophy is on the rise, and factors that are driving its market growth include increased awareness campaigns about the disorder, the development of mutation-specific therapies, the rise in product pipelines, the introduction of therapies like Exondys51 and Translarna, and the use of corticosteroid-based anti-inflammatory drugs.

The introduction of novel pharmaceuticals and treatments, disease-modifying treatments, significant backing from numerous firms for drug research, and support from patient advocacy groups on the regulatory approval process are the main factors driving the global market for duchenne muscular dystrophy.

North America dominated the global duchenne muscular dystrophy market. The market in North America is expected to expand as a result of a number of important factors, including the rising prevalence of muscular dystrophy in the region, FDA drug approval, strong healthcare infrastructure supported by supportive government regulations, and medical reimbursement in the region and due to anticipated product launches.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Global Duchenne Muscular Dystrophy Market

Report ID: UCMIG35I2135 | Region: Global | Published Date: April, 2024 | Pages: 165 | Tables: Figures:

Epilepsy Drugs Market
Buy Now GET FREE SAMPLE
Global Duchenne Muscular Dystrophy Market

Report ID: SQMIG35I2125 | Region: Global | Published Date: April, 2024 | Pages: 248 | Tables: 59 | Figures: 75

Global Active Pharmaceutical Ingredients Market
Buy Now GET FREE SAMPLE
Global Duchenne Muscular Dystrophy Market

Report ID: UCMIG35I2118 | Region: Global | Published Date: April, 2024 | Pages: 165 | Tables: Figures:

Psoriasis Drugs Market
Buy Now GET FREE SAMPLE
Global Duchenne Muscular Dystrophy Market

Report ID: SQMIG35I2225 | Region: Global | Published Date: April, 2024 | Pages: 157 | Tables: 64 | Figures: 75

Global Veterinary Services Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Duchenne Muscular Dystrophy Market

Product ID: SQSG35I2036

$5,300
BUY NOW GET FREE SAMPLE